Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Rituximab (a monoclonal antibody against CD20-expressing B lymphocytes) is increasingly used for antibody-mediated autoimmunity and lymphoproliferative disorders. While safety data for children are limited, recent reports have highlighted neutropenia and persistent hypogammaglobulinaemia1 2 as potential consequences of rituximab therapy. Rarely, rituximab may unveil inborn errors of immunity presenting with autoimmunity.1
We wish to highlight the risk of prolonged time to IgG recovery, particularly among those starting treatment at a younger age, and emphasise the importance of regular monitoring of IgG and IgM levels.
We retrospectively analysed 5 years of rituximab administration at our regional tertiary children’s hospital. Between 2015 and 2020, 180 patients received 583 doses of rituximab. We excluded patients who received rituximab within 6 months of data collection, with inborn errors of immunity, …
Contributors CT, KH, NV, AB, FM and EW conceived the work. CT and EW collected data and performed analyses. All authors contributed to the generation and critical review of this manuscript.
Funding CT is supported by the Job Research Foundation.
Disclaimer The funder had no involvement in the generation of this manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.